RMD

1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M

YTD YTD

1 Year 1Y

5 Years 5Y

About Resmed Inc.

ResMed pioneers innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Its comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, the company improves quality of life, reduces the impact of chronic disease, and lowers costs for consumers and healthcare systems in more than 140 countries.
CEO
Michael Farrell
Employees
7770
Headquarters

9001 Spectrum Center Blvd
San Diego, California 92123-1438
Phone: 18587462400
www.resmed.com

News

Eli Lilly’s GLP-1 impact on ResMed is overblown: Barron’s
Jul 13, 2024 19:34pm

ResMed (RDM) remains attractive despite a recent selloff driven by positive sleep data for Eli Lilly''s (LLY) GLP-1, tirzepatide, Barron''s says. Read more here.


Source:Seeking Alpha
ResMed: Potentially Undervalued Amid Increasing Sleep Apnea Awareness
Jul 03, 2024 22:19pm

ResMed''s USP is in its integrated approach to sleep and respiratory care, combining innovative hardware with advanced software. Find out more on RMD stock here.


Source:Seeking Alpha
ResMed: Asymmetrical Value Opportunity With High Prospect Of Re-Rating
Jul 03, 2024 12:44pm

ResMed’s competitive advantages in the sleep domain are durable, and its underlying business remains strong. Read why I''m bullish on RMD stock here.


Source:Seeking Alpha
Why Investors Are Eyeing ResMed Inc (RMD): The Key Drivers of Market Outperformance and Growth ...
Jul 01, 2024 16:00pm

Why Investors Are Eyeing ResMed Inc (RMD): The Key Drivers of Market Outperformance and Growth Potential


Source:GuruFocus
Sound Investments: 3 Stocks to Buy for a Good Night’s Rest
Jun 29, 2024 13:00pm

When one thinks about safe stocks to buy, investors generally think of blue-chip large-cap companies such as Berkshire Hathaway (NYSE: BRK-A , NYSE: BRK-B ) or Microsoft (NASDAQ: MSFT ). However, manufacturers of beds, sleep apnea machines and proper lighting are participating in a $585 billion global sleep economy. A November 2023 article from Harvard Health Publishing, the media division of Harvard Medical School, published 8 secrets to a good night’s sleep. “We all have trouble sleeping from time to time, but when insomnia persists day after day, it can become a real problem. Beyond making us tired and moody, a lack of sleep can have serious effects on our health, increasing our propensity for obesity, heart disease, and type 2 diabetes,” Harvard Health’s introduction stated . There is no question sleep disorders are a huge problem to daily productivity. It’s estimated that poor sleep costs the U.S. economy $400 billion annually, which represents 2.3% of the country’s GDP. I’m confident the eight secrets will lead us to the safe stocks to buy benefiting from the sleep economy.


Source:InvestorPlace
ResMed cut at Oppenheimer after Eli Lilly’s tirzepatide sleep apnea data
Jun 25, 2024 17:37pm

No summary available.


Source:Seeking Alpha
Inspire Medical, ResMed decline following Lilly tirzepatide sleep apnea data
Jun 24, 2024 19:17pm

Inspire Medical Systems (INSP) and ResMed (RMD) see significant drops in trading after positive data on Eli Lilly''s tirzepatide as a sleep apnea treatment. Read more here.


Source:Seeking Alpha
"Breakthrough" Eli Lilly Weight-Loss Drug Data To Treat Obesity & Sleep Apnea, Sends CPAP Device-Makers Plunging
Jun 24, 2024 17:45pm

"Breakthrough" Eli Lilly Weight-Loss Drug Data To Treat Obesity & Sleep Apnea, Sends CPAP Device-Makers Plunging Shares of medical equipment companies specializing in sleep apnea treatments nosedived on Monday after a new study from Eli Lilly and Company revealed that its tirzepatide weight-loss drug significantly reduced the severity of sleep apnea. On Friday, Eli Lilly announced new results from its SURMOUNT-OSA phase 3 clinical trials evaluating tirzepatide injection to treat moderate-to-severe obstructive sleep apnea, otherwise known as OSA. Tirzepatide, branded as Mounjaro (a diabetes drug) and Zepbound (a weight loss drug), reduced moderate-to-severe OSA in obese adults with and without positive airway pressure (PAP) therapy. Eli Lilly and Company (NYSE: LLY) announced detailed results from the SURMOUNT-OSA phase 3 clinical trials evaluating tirzepatide injection (10 mg or 15 mg) for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, with and without positive airway pressure (PAP) therapy .


Source:Zero Hedge
Stocks making the biggest moves midday: ResMed, Affirm, Nvidia, Anheuser-Busch and more
Jun 24, 2024 16:39pm

These are the stocks posting the largest moves midday.


Source:CNBC
Top Stock Movers Now: Affirm, Nvidia, ResMed, and More
Jun 24, 2024 16:29pm

U.S. equities were mixed at midday Monday, June 24, 2024 as most sectors gained, but tech stocks lost ground.


Source:Investopedia